Shares of Dr. Reddy's Laboratories (NSE:DRREDDY) jumped about 4% after the FDA closed a Pre-License Inspection at its Bachupally biologics site with a Form 483 noting seven observations, as analysts eye a potential Q4 2026–27 Abatacept biosimilar launch that could boost FY28–29 earnings amid resolved older-block issues.
Previous Week Recap
- FDA Inspection At Dr. Reddy's: DRREDDY rose about 4% after the FDA completed a Pre-License Inspection at Dr. Reddy’s Bachupally biologics plant; the inspection closed with a Form FDA 483 noting seven observations.
- Abatacept Biosimilar Launch Anticipated: Analysts say Dr. Reddy's (DRREDDY) may launch an Abatacept biosimilar around Q4 2026–27; global Abatacept market ~USD 3.7B. Regulatory clearance and FY28–FY29 earnings impact noted.
- Bachupally Site Contamination Update: Dr. Reddy's Bachupally site has two blocks: older one tied to Rituximab, newer one tied to Abatacept. Past contamination at the older block may be resolved; current issues mainly in the newer block.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.